|
|
401 Professional Drive, Suite 200
Gaithersburg, MD 20879 USA
phone:240-632-0094
fax:240-632-0465
|
|
| Symbol |
Private |
| Founded |
0 |
| Employees |
|
|
|
| www.sequoiapharma.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Antiviral therapeutics for drug-resistant HIV and HCV. |
|
| Management |
| Steve Skolsky; John W. Erickson, Ph.D.; Brian Wynne, MD.; Raymond Dagger Ph.D.; Michael Eissenstat, Ph.D.; Sergei V. Gulnik, Ph.D.; Robert Guttendorf, Ph.D.; Abelardo M. Silva, Ph.D.; Elena Afonina, Ph.D.; Douglas Ludtke, D.Sc
|
| |
|
|
| |
|
| Keywords |
| antiviral, drug-resistant, HIV, HCV, enzymes, receptor, HIVAIDS |
|
|
|
| Description |
|
Sequoia Pharmaceuticals, Inc. is focused on the discovery and development of novel antiviral therapeutics for combating drug-resistant HIV and HCV. |
|
| Technology / Differentiation |
| The foundation of Sequoia's novel Resistant-Repellent technology is a drug discovery tool that enhances the efficiency with which drugs are designed. It is based on an understanding of the chemical and physical nature of the molecular targets ' the enzymes and receptors to which drugs bind ' combined with an understanding of the molecular mechanisms that cause drug resistance. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members